Safety and equity are the strategy.

Rejuvenation research must include safety limits against uncontrolled cell-identity loss and tumour risk. Where a mechanism cannot be bounded, we do not advance it — we redesign the question.

In practice: dose-limited, reversible protocols; identity markers checked before any scale-up.

Biology rarely gives something for nothing. Naive gene deletions can remove protections we did not know we needed, so we protect genetic diversity rather than optimising toward a single template.

In practice: no broad editing; variation preserved across cohorts and populations.

We favour repairing existing biology over replacing it. Continuity of self is not a marketing line — it is the reason the work has meaning.

In practice: maintenance-first concepts; replacement framed as a last resort, not a feature.

Researching toward affordable, scalable models — not only ultra-premium therapies. A longevity technology available only to the wealthiest would be a failure of the field, not a success for it.

In practice: access modelled at the research-design stage, with cost per treatment as an explicit variable.

Every programme is designed to meet MHRA requirements in the UK, FDA requirements in the US, and independent ethics review — before any human research, not after.

In practice: no human research without approvals; no claims ahead of evidence.